Clinical trials: Food Sensitivity
- Condition Food Sensitivity
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Cow's Milk Protein Allergy
Tolerance and Growth Outcomes in Children Diagnosed With Cow's Milk Protein Allergy and Prescribed an Extensively Hydrolyzed Casein Formula (Damira 2000©) in Spain
Damira 2000© is a 100% extensive casein hydrolysate (eHCF). It is formulated to help reverse growth retardation as a result of cow's milk proteins allergy (CMPA), to be well tolerated and to help improve symptoms.Damira 2000 is…
- Trial name
- DELISA (NCT06273371)
- Testing
- Damira 2000 Infant formula
- Where
- 8 sites in Spain
- Volunteers
- 61 people
- Sponsor
- Lactalis
Cow's Milk Allergy
Growth, Safety and Tolerance of a Rice Protein Hydrolysate Formula in Infants With Cow's Milk Protein Allergy
This is a multicenter, controlled, randomized, prospective, non-inferiority, double blind intervention trial to evaluate the children growth (at 6, 9 and 12 months) using a rice hydrolysed protein formula compared to an…
- Trial name
- GRITO-14 (NCT02405923)
- Testing
- HRF, eHF
- Where
- 5 sites in France, Spain
- Volunteers
- 117 people
- Sponsor
- Laboratorios Ordesa
Peanut Allergy
Oral Desensitization to Peanut in Peanut-Allergic Children and Adults Using Characterized Peanut Allergen OIT
This is a multi-center, randomized, double-blind placebo controlled study of efficacy and safety of characterized peanut oral immunotherapy in peanut allergic individuals.
- Trial name
- ARC001 (NCT01987817)
- Testing
- AR101 powder provided in capsules
- Where
- 8 sites in United States
- Volunteers
- 56 people
- Sponsor
- Aimmune Therapeutics, Inc.
Growth, Allergy
Growth, Tolerance in Healthy Infants Fed a Partially Hydrolyzed Rice Protein
The purpose of this study is to assess growth and global tolerance in healthy new born infants with minor gastrointestinal troubles and/or allergic risk, fed an experimental partially hydrolyzed rice protein infant formula.
- Trial name
- Rose (NCT00997971)
- Testing
- Modilac Rose 1
- Where
- 9 sites in France
- Volunteers
- 86 people
- Sponsor
- Sodilac
Cow Milk Allergy
Hypoallergenicity Evaluation of a New Extensively Hydrolyzed Formula
Infants/children with cow's milk allergy will take part in 2 double-blinded placebo-controlled food challenges (DBPCFC) of 2 extensively hydrolyzed formulas in random order.
- Trial name
- NCT03236207
- Testing
- Test extensively hydrolyzed formula, Control extensively hydrolyzed formula
- Where
- 12 sites in United States
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Société des Produits Nestlé (SPN)
Cow Milk Allergy
A Growth and Hypoallergenicity Study of a New Formula for Infants With Cow Milk Allergy
This study involves the use of 2 different Neocate formulas: a control formula called Neocate Infant and a test Neocate formula.
- Trial name
- CMA (NCT00664768)
- Testing
- Neocate Infant, new Neocate
- Where
- 22 sites in United States
- Volunteers
- 126 people
- Sponsor
- Nutricia North America
Food Allergy, Wheat Hypersensitivity
A Study to Evaluate the Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Characteristics of LP-003 Injection in Participants With Wheat Allergy
This is a multicenter, randomized, open-label Phase II clinical study to evaluate the safety, efficacy, pharmacokinetic (PK), pharmacodynamic (PD) and immunogenicity profiles of LP-003 injection in participants with Wheat…
- Trial name
- NCT07816432
- Testing
- LP-003 Injection
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Longbio Pharma (Suzhou) Co., Ltd.
Peanut Allergies
Study to Evaluate the Safety, Pharmacokinetic, and Pharmacodynamic Effects of MY006 in Healthy Volunteers and Patients With Peanut Allergy
The goal of this clinical trial is to evaluate the safety, pharmacokinetics, and effectiveness of MY006, a therapy designed to prevent severe or potentially life-threatening allergic reactions caused by accidental peanut intake.
- Trial name
- NCT07287033
- Testing
- MY006 Low Dose, MY006 Mid Dose, MY006 High Dose
- Where
- 9 sites in United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Mabylon AG
Peanut Allergy
PALISADE Follow-on Study (ARC004)
The purpose of this study is to demonstrate the safety, tolerability, and efficacy of AR101 through oral immunotherapy (OIT) in peanut-allergic children and adults who have completed the ARC003 study.
- Trial name
- NCT02993107
- Testing
- AR101
- Where
- 65 sites in United States, Canada and 7 more
- Volunteers
- 388 people
- Sponsor
- Aimmune Therapeutics, Inc.
Inflammatory Bowel Diseases, Irritable Bowel Syndrome
Fecal Calprotectin Collection Protocol
The primary objective is to obtain stool samples from subjects diagnosed with , and displaying signs and/or symptoms of IBD and/or IBS will be evaluated in this study.
- Conditions
- Inflammatory Bowel Diseases, Irritable Bowel Syndrome, Ulcerative Colitis, Crohn Disease
- Trial name
- CALFE (NCT03143517)
- Testing
- Stool collection
- Where
- 13 sites in United States
- Volunteers
- 240 people
- Sponsor
- DiaSorin Inc.
Asthma
Effect of Medical Food on Reducing Asthma Symptoms in Asthmatic Children
To determine the effect of medical food on reducing asthma symptoms in asthmatic children.
- Trial name
- NCT01087710
- Testing
- medical food with EPA and GLA, vitamins and minerals, medical food minus EPA and GLA, antioxidant vitamins/minerals
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Abbott Nutrition
Peanut Allergy
Follow-up of the PEPITES Study to Evaluate Long-term Efficacy and Safety of Viaskin Peanut in Children
This is an open-label, follow-up study for subjects who completed the PEPITES study. Subjects will be offered enrollment in this follow-up study to receive Viaskin Peanut 250 μg for 2 additional years if previously on active…
- Trial name
- PEOPLE (NCT03013517)
- Testing
- Viaskin Peanut 250µg
- Where
- 31 sites in United States, Australia and 3 more
- Volunteers
- 300 people
- Sponsor
- DBV Technologies
Allergy, Peanut
Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Children 4-7 Years of Age
The primary purpose of this study is to assess the efficacy and safety of daily DBV712 250 micrograms (mcg) to induce desensitization to peanut in peanut-allergic children 4-7 years of age over a 12-month double-blind…
- Trial name
- VITESSE (NCT05741476)
- Testing
- DBV712
- Where
- 87 sites in United States, Australia and 7 more
- Volunteers
- 600 people
- Sponsor
- DBV Technologies
Milk Hypersensitivity
Prevention of Cow's Milk Allergy in Children
Impact of fermented milk in prevention of cow's milk allergy in new born and infants
- Trial name
- NCT00792090
- Testing
- Fermented milk, Standard milk
- Where
- 2 sites in France
- Volunteers
- 142 people
- Sponsor
- Bledina
Cow's Milk Allergy
Hypoallergenicity of a Hydrolyzed Protein Infant Formula
Study to demonstrate hypoallergenicity of a hydrolysed protein infant formula in a population of children with confirmed cow's milk allergy.
- Trial name
- HYPO STORY (NCT05731206)
- Testing
- Hydrolyzed protein infant formula, commercially available hypoallergenic infant formula
- Where
- Italy
- Volunteers
- 29 people
- Sponsor
- Nutricia Research
Peanut Allergy
Follow-up of the VIPES Study to Evaluate Efficacy and Safety of Viaskin Peanut in Adults and Children
The objectives of this open-label follow-up study for subjects who previously were randomized and have completed the VIPES study for the treatment of peanut allergy, are: To assess the efficacy of Viaskin Peanut after up to 36…
- Trial name
- OLFUS-VIPES (NCT01955109)
- Testing
- Viaskin Peanut 250 mcg
- Where
- 22 sites in United States, Canada and 2 more
- Volunteers
- 171 people
- Sponsor
- DBV Technologies
Peanut Allergy
Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Young Children 1-3 Years of Age
The study aims to assess the safety and efficacy of Viaskin Peanut to induce desensitization to peanut in peanut-allergic children 1 to 3 years of age after a 12-month treatment by EPicutaneous ImmunoTherapy (EPIT).
- Trial name
- EPITOPE (NCT03211247)
- Testing
- Part A Viaskin Peanut 250 mcg, Part A Viaskin Peanut 100 mcg, Part B Viaskin Peanut 250 mcg
- Where
- 51 sites in United States, Australia and 6 more
- Volunteers
- 414 people
- Sponsor
- DBV Technologies
Milk Hypersensitivity, Food Sensitivity
Evaluation of the Efficacy of a New Formula in Infants With Cow's Milk Protein Allergy
The aim of the study is to show the efficacy, tolerance and nutritional adequacy of a newly developed hydrolyzed rice formula in infants with a proven cow's milk protein allergy.
- Conditions
- Milk Hypersensitivity, Food Sensitivity, Protein Allergy
- Trial name
- Paradice (NCT01998074)
- Testing
- extensively hydrolyzed rice protein formula
- Where
- Belgium
- Sponsor
- United Pharmaceuticals
Allergy, Peanut Allergy
Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)
The primary objective of this study is to assess the 6-month safety of DBV712 250 micrograms (mcg) in subjects 1 through 3 years of age with peanut allergy.
- Trial name
- NCT07003919
- Testing
- DBV712 250 mcg
- Where
- 91 sites in United States, Australia and 6 more
- Volunteers
- 480 people
- Sponsor
- DBV Technologies
Cow Milk Allergy
Growth, Safety and Tolerance of a Hydrolyzed Protein Infant Formula
This is a single arm, open label, multicenter intervention trial to evaluate growth parameters, cow's milk related symptoms, gastrointestinal tolerance and safety in infants with cow's milk allergy receiving a hydrolyzed protein…
- Trial name
- STORY (NCT05618704)
- Testing
- Hydrolyzed protein infant formula
- Where
- Poland
- Volunteers
- 69 people
- Sponsor
- Nutricia Research